What Women Over 40 Actually Need From a Hormone Protocol — And What Most Get Wrong

A woman walks into a telehealth appointment at 42. She's sleeping poorly, carrying 12 pounds she couldn't shift even after cleaning up her diet, and her libido has been absent for eight months. The doctor orders a basic TSH panel, tells her everything looks "normal," and sends her home. This scenario plays out thousands of times a week. The problem isn't that the doctor lied — her TSH probably was normal. The problem is that a TSH panel, on its own, is the wrong test for what she's actually experiencing.

Perimenopause begins, on average, four years before the final menstrual period, meaning most women are dealing with measurable hormonal fluctuation somewhere between 38 and 46. A protocol that doesn't account for this window misses the entire point.

---

What the Lab Panel Should Actually Include

The standard "hormone check" that most GPs order covers TSH, maybe a CBC, occasionally estradiol. A functional hormone protocol for a woman in her 40s requires considerably more granularity.

At minimum: estradiol (E2), progesterone, total and free testosterone, DHEA-S, cortisol (ideally four-point salivary or a DUTCH panel), fasting insulin, and sex hormone-binding globulin (SHBG). SHBG matters more than most practitioners acknowledge — a woman can have technically normal total testosterone while SHBG binds enough of it to render her functionally deficient. Free testosterone below 1.0 ng/dL is a clinically relevant number that often goes unreported because it doesn't fall outside the lab's flagged range.

Progesterone deserves particular attention. In perimenopause, progesterone drops before estrogen does, which is why sleep disruption, anxiety, and cycle irregularity often arrive before hot flashes. Protocols that skip progesterone entirely — or add it only after estrogen is already prescribed — are working backwards.

---

Estrogen: Delivery Route Changes Everything

The Endocrine Society's 2015 clinical practice guideline on menopause distinguishes clearly between oral and transdermal estrogen on cardiovascular risk grounds. Oral estrogen increases hepatic synthesis of clotting factors; transdermal estrogen bypasses first-pass liver metabolism and carries a more neutral clotting profile. For most women over 40, transdermal estradiol — typically 0.05 mg to 0.1 mg/day via patch, or an equivalent gel dose — is the more defensible starting point unless a specific contraindication exists.

Bioidentical versus synthetic is a separate argument, and a noisier one than the evidence warrants. 17-beta estradiol is the bioidentical molecule and is also FDA-approved in multiple forms, including Vivelle-Dot and Estrace. The compounded cream conversation is distinct from the bioidentical conversation — and conflating the two consistently muddles clinical decision-making.

---

Testosterone: The Conversation That Keeps Getting Delayed

There is no FDA-approved testosterone product for women in the US as of mid-2026. That regulatory gap has not reduced clinical use — it has pushed it into off-label territory, where it has operated for decades. Most prescriptions involve compounded testosterone cream dosed between 0.5 mg and 2 mg per day, applied transdermally.

The evidence base is stronger than the regulatory status implies. The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Davis et al., The Journal of Clinical Endocrinology & Metabolism) found that transdermal testosterone improved sexual function in postmenopausal women, with the strongest data in the domain of hypoactive sexual desire. The same review found that physiologic dosing — keeping free testosterone within the upper quartile of the normal female range — produced no adverse cardiometabolic effects in trials running up to 24 months.

Women are also significantly underserved in testosterone monitoring. Many hormone optimization clinics include regular testosterone checks as part of ongoing protocols; the better platforms recheck levels at 6–8 weeks after any dose adjustment rather than waiting for annual reviews.

---

Where Peptides Fit Into the Protocol

Peptide therapy functions as an adjunct, not a standalone intervention. Ipamorelin, a growth hormone secretagogue, is frequently added to female hormone protocols at doses of 100–300 mcg per injection, typically administered before sleep to align with the natural GH pulse. Declining GH pulsatility through the 40s contributes to body composition changes, sleep quality loss, and recovery impairment — a symptomatic cluster that overlaps substantially with perimenopause but does not respond to estrogen or testosterone alone.

Tesamorelin, a GHRH analogue, carries stronger clinical data on visceral fat reduction — originally studied in HIV-associated lipodystrophy at 2 mg/day — and is now used off-label in metabolic protocols for women dealing with abdominal fat redistribution that doesn't respond to diet or exercise. Both peptides work most efficiently once the sex hormone foundation is addressed; running them in estrogen-deficient or insulin-resistant terrain produces diminished returns.

---

How to Find a Protocol That Matches This Level of Specificity

Most primary care settings won't run this full panel, interpret SHBG in context of symptoms, or adjust testosterone by free levels. Online hormone programs have filled that gap at varying quality levels. What separates the higher-quality programs: they run a DUTCH or equivalent cortisol assessment alongside sex hormones, they include a physician review of all results rather than algorithm-driven prescribing, and they set clear retest milestones — typically at 6 and 12 weeks post-initiation.

Pricing in 2026 ranges widely. A one-time comprehensive panel through a specialty clinic typically runs $350–$650 out of pocket. Ongoing monitoring subscriptions — quarterly labs plus clinical review — generally land between $150 and $300 per month depending on medications included. Programs quoting $79/month for the full picture described above should be asked, specifically, what that price covers — it rarely covers everything listed here.

---

The Actual Takeaway

A complete female hormone protocol in 2026 is not complicated, but it is specific. It requires free testosterone, SHBG, and progesterone alongside estradiol. It requires a delivery route decision based on cardiovascular risk factors, not convenience. It requires follow-up labs timed to dose changes, not calendar years. Annual panels and brief phone call reviews constitute a monitoring protocol for a different purpose — not hormone optimization. Those two things are not interchangeable. To compare structured programs that operate at this level of specificity, find a hormone clinic using filters that match your goals before committing to any ongoing subscription.

---

Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.

---